Reactive oxygen species (ROS) have a crucial role in melanoma differentiation-associated gene-7 (MDA-7)/interleukin-24 (IL-24)-induced cancer cell apoptosis. However, cancer cell has a series of protective mechanisms to resist ROS damage. Nuclear factor erythroid 2-related factor 2 (Nrf2) activates antioxidant response element (ARE)-mediated gene expression involved in cellular protection against oxidative stress. As the Nrf2 repressor, Kelch-like ECH-associated protein-1 (Keap1) sequesters Nrf2 in cytoplasm to block Nrf2 nuclear translocation. In the present study, administration of MDA-7/IL-24 by means of tumor-selective replicating adenovirus (ZD55-IL-24) was used to investigate whether ZD55-IL-24 could attenuate Nrf2-mediated oxidative stress response in cancer cell. We found that ZD55-IL-24 effectively strengthened the association between Nrf2 and Keap1 to restrict Nrf2 nuclear translocation, thereby inhibiting ARE-dependent transcriptional response. To evaluate the detailed mechanism underlying the suppression of ZD55-IL-24 on Nrf2-mediated oxidative stress response, we further tested three different mitogen-activated protein kinase (MAPK) signaling pathways in A549 and HeLa cells transfected by ZD55-IL-24. Our data showed that ZD55-IL-24 inhibited extracellular signal-regulated kinase (ERK) signal pathway but activated p38 and c-Jun-NH2-kinase (JNK) signal pathways to exert the tumor-specific apoptosis. Moreover, ERK pathway inhibitor U0126 prevented Nrf2 phosphorylation at Ser40 to retard Nrf2 nuclear translocation, thus decreasing antioxidant gene transcription. In contrast, p38 pathway inhibitor SB203580 obviously promoted the dissociation of Nrf2 from Keap1 to promote antioxidant gene transcription. However, JNK pathway had no effect on Nrf2 subcellular localization or the association of Nrf2 with Keap1. Conclusively, our results indicate that ZD55-IL-24 inhibits Nrf2-mediated oxidative stress response not only by activating p38 signal pathway to potentiate the association of Nrf2 and Keap1 but also by suppressing ERK signal pathway to postpone Nrf2 nuclear translocation. Given the 'dark' side of Nrf2 on carcinoma cell survival and chemoresistance, our study provides a novel explanation about MDA-7/IL-24-induced cancer-specific apoptosis and therapeutic sensitization through suppression of the cytoprotective system.
INTRODUCTION
Melanoma differentiation associated gene-7/interleukin-24 (MDA--7/IL-24) uniquely displaying induction of irreversible growth arrest and terminal differentiation of human melanoma cells is identified as a novel member of the IL-10 family cytokines. 1, 2 Moreover, MDA-7/IL-24-induced cancer cells apoptosis exists not only in the context of melanoma but also in diverse human cancers without affecting normal cells, thus exerting cancerspecific killing. [3] [4] [5] This apoptosis-inducing property of MDA-7/IL-24 has been partially due to the generation of reactive oxygen species (ROS). 6, 7 Previous studies also demonstrate that extra ROS strengthen the tumor-specific killing of MDA-7/IL-24, whereas antioxidants like N-acetyl-L-serine attenuate MDA-7/IL-24-induced apoptosis, 8, 9 suggesting that ROS-coupled mitochondria dysfunction and DNA damage are associated with MDA-7/IL-24-mediated cancer-specific apoptosis.
ROS such as superoxide radical anion, hydrogen peroxide, singlet oxygen and hydroxyl radical ion are regarded as the modifiers of cellular functions, affecting development, growth, aging and survival. 10 Overproducing ROS or disturbing the critical balance of internal redox state can trigger a serial chain of reactions to damage the cellular integrity. 11 However, cells have developed their own defense mechanism: phase II detoxifying enzymes including glutathione S-transferase, NAD(P)H quinone oxidoreductase 1 (NQO1), γ-glutamylcysteine synthetase and heme oxygenase 1 protect cells against such ROS-induced damages by converting the reactive electrophiles to less toxic and more readily excretable products. [12] [13] [14] [15] Since MDA-7/IL-24-mediated cancer selective apoptosis is closely related to ROS induction, we want to further detect whether MDA-7/IL-24 also regulates the cellular defensive protection.
Nuclear factor erythroid 2-related factor 2 (Nrf2), as the antioxidant response executor, coordinates induction of a battery of genes encoding defensive proteins through binding to antioxidant response element (ARE). 16, 17 Under basal condition, Nrf2 is sequestered by an inhibitor protein named Kelch-like ECH-associated protein-1 (Keap1) 18 in the cytoplasm. However, oxidative or chemical stress disrupts Nrf2/Keap1 complex and permits Nrf2 to translocate into the nucleus where it enhances the transcription of phase II detoxifying genes by binding to ARE sequences. 19, 20 Some recent studies have demonstrated that Nrf2 is phosphorylated at Ser40, which further affects Nrf2 nuclear translocation. 21, 22 Given that phosphorylation of Ser40 is necessary for Nrf2 dissociation from Keap1, 23 we have more interest to explore whether MDA-7/IL-24 will affect the phosphorylation of Nrf2 at Ser40 and investigate the relevant molecular mechanism.
Mitogen-activated protein kinase (MAPK) pathways including extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK) and p38 MAPK pathways have been reported to be involved in ARE-mediated gene expression. [24] [25] [26] The ERK pathway is activated by a large variety of mitogens and phorbol esters, whereas the JNK and p38 pathways are stimulated mainly by environmental stress and inflammatory cytokines. [27] [28] [29] The previous studies show that MDA-7/IL-24 regulates three MAPK pathways through phosphorylation of protein kinase R-like endoplasmic reticulum kinase (PERK) that further reduces ERK1/2 and AKT phosphorylation but activates JNK1/2 and p38 MAPK pathways, suggesting that these MAPK pathways have been implicated in MDA-7/IL-24-mediated cytotoxic effect. 9, [30] [31] [32] However, whether MDA-7/IL-24 could regulate the Nrf2-mediated cytoprotective responses via these MAPK pathways and the molecular mechanism underlying this effect remain to be elucidated.
In this study, ZD55-IL-24 as a conditionally replicating adenovirus mediated the expression of MDA-7/IL-24. We hypothesized that ZD55-IL-24 regulated Nrf2 phosphorylation via some MAPK signaling pathways to subsequently impact Nrf2 activation in one of the several ways including the inhibition of Nrf2-Keap1 dissociation, the retard of Nrf2 nuclear translocation and the attenuation of its downstream ARE-mediated gene transcription. These findings demonstrate the novel function of ZD55-IL-24 in regulation of Nrf2 activity and provide a valuable mechanism, by which MDA-7/IL-24 not only produces ROS to induce cancer cell killing but also diminishes Nrf2-mediated defense machinery, thereby synergistically facilitating cancer-specific apoptosis.
MATERIALS AND METHODS

Cells and reagents
The human lung adenocarcinoma epithelial (A549) cell line and the human Henrietta Lacks (HeLa) cell line were obtained from Shanghai Cell Collection (Shanghai, China). A549 and HeLa cells were cultured in a 37°C incubator with 5% CO 2 in Dulbecco's Modified Eagle's Medium (DMEM; GIBCO BRL, Grand Island, NY) containing 10% fetal bovine serum (FBS, GIBCO-BRL), 2 mM L-glutamine and 100 units per ml penicillin/streptomycin. JNK inhibitor SB600125, p38 inhibitor SB203580, ERK inhibitor U0126, IL-24-siRNA and scrambled control siRNA, antibodies that recognize Keap1 and Nrf2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against JNK1/2(p46/p54), ERK1/2(p42/p44), p38MAPK, phospho-JNK1/2(Thr183/ Tyr185), phospho-ERK1/2(Thr202/Tyr204) and phospho-p38 MAPK (Thr180/Tyr182) were purchased from Cell Signaling Technology (Danvers, MA). Anti-Nrf2 (phosphor-Ser40) antibody was purchased from Abcam (Cambridge, UK).
Virus construction and production pZD55, the E1B 55-kDa-deleted oncolytic adenovirus construction plasmid; pCA13, the E1-deleted adenovirus shuttle plasmid; and ZD55-enhanced green fluorescent protein (EGFP) with reporter gene EGFP were kindly provided by Professor Liu (Xin-Yuan Liu, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China). IL-24 was first cloned into pCA13 to form pCA13-IL-24. Then, IL-24 excised from pCA13 was subcloned into pZD55 to construct pZD55-IL-24. Oncolytic adenovirus, ZD55-IL-24 was generated in HEK293 cells (Shanghai Cell Collection) by homologous recombination between pZD55-IL-24 and the adenovirus packaging plasmid pBHGE3 (Microbix Biosystems, Toronto, Canada), respectively. Large-scale purification of all adenovirus particles was performed by ultracentrifugation with cesium chloride according to standard techniques. The titers were determined using a plaque assay on HEK293 cells.
Transient transfection and luciferase assay A549 cells were grown in monolayer cultures in 12-well plates in DMEM supplemented with 10% FBS. Then, cells were co-transfected with 0.1 μg of reporter construct human nicotinamide quinone oxidoreductase 1(NQO1)-ARE-Luc and 10 times less quantities of firefly Renilla luciferase encoded by plasmid pRL-TK. Renilla luciferase was used as an internal control in each transfection. After 24 h of transfection, the cells were washed with 1 × phosphate-buffered saline (PBS) and lysed in 1 × passive lysis buffer from the Dual-Luciferase reporter assay system kit (Promega, Madison, WI). The luciferase activity was measured using the procedures described previously and plotted. 33 Renilla luciferase activity was used to normalize the firefly luciferase activity to control the sample-to-sample variations of transfection efficiency. All reporter gene assays were repeated in at least three independent transfections.
Western blotting
After specific treatments, A549 and HeLa cells were incubated in lysis buffer containing 20 mmol l − 1 Tris-HCl (pH 7.5), 1% Triton X-100, 150 mmol l − 1 NaCl, 10% glycerol, 1 mmol l − 1 Na 3 VO 4 , 50 mmol l − 1 NaF, 100 mmol l − 1 phenylmethylsulfonyl fluoride, and a commercial protease inhibitor mixture (Roche Molecular Biochemicals, Mannheim, Germany) for 20 min on ice. Cytoplasmic and nuclear cell fractions were separated by using the Active Motif nuclear extract kit (Active Motif, Carlsbad, CA) by following the manufacturer's protocol. After insoluble debris was pelleted by centrifugation at 14 000 g for 15 min at 4°C, the supernatants were collected and determined for protein content using the Bradford method (Bio-Rad Laboratories, Hercules, CA). Proteins (80 μg) were resolved under denaturing conditions by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) (10%) and transferred onto nitrocellulose membranes. After blocking for 2 h in PBS with 0.1% Tween-20 (PBST) and 3% bovine serum albumin (BSA), membranes were incubated overnight at 4°C with the appropriate primary antibody in PBST containing 3% BSA. Membranes were then washed and incubated with alkaline phosphataseconjugated goat anti-rabbit IgG or anti-mouse IgG (Sigma, St Louis, MO, USA, 1:10 000) in PBST for 2 h and developed using NBT/BCIP color substrate (Promega).
Immunoprecipitation
For immunoprecipitation, cytosolic fractions (each containing 400 μg of proteins) were diluted fourfold with HEPES buffer containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 10% glycerol, 1% Triton X-100 and 1 mM each of EGTA, EDTA, PMSF and Na 3 VO 4 . The samples were then preincubated for 1 h with 20 μl protein A agarose and centrifuged to remove any nonspecifically adhered proteins from the protein A agarose. The supernatant was then incubated with 2 μg specific antibodies overnight at 4°C. After the addition of protein A agarose, the mixture was incubated at 4°C for an additional 2 h. Samples were triple washed with HEPES buffer and eluted by SDS-PAGE) loading buffer then boiled at 100°C for 5 min. Immune complexes were separated by 10% SDS-PAGE and analyzed by western blotting as described above.
Immunocytofluorescence A549 cells (5.0 × 10 5 per well) were cultured in 6-well plate with sterilized coverslip and treated with or without the JNK, p38 and ERK pathway inhibitors after transfection of ZD55-IL-24, respectively. These coverslips were fixed with 4% paraformaldehyde for 10 min at room temperature, then washed with PBS for 5 min and permeabilized in 0.2% prechilled Triton-100/PBS for 10 min at 4°C. These cells were washed with PBS and incubated with 0.5% BSA/PBS blocking buffers for 1 h at room temperature. The polyclonal antibody anti-Nrf2 diluted 1:200 in 0.5% BSA/PBS for overnight at 4°C. Cells were washed three times for 5 min with PBST, incubated for 1 h with the secondary anti-rabbit IgG antibody conjugated with Alex Fluor 488 fluorochrome (diluted 1:50 in 0.5% BSA/PBS), washed three times for 5 min with PBS. Finally, these coverslips were mounted with 10 μl of anti-fade mounting medium (90% glycerol, 20 mM Tris-HCl pH 7.5, 0.1% DABCO) and visualized with a fluorescence microscope.
Annexin V apoptosis assay
Annexin V-binding assay was used according to the manufacturer's instructions. Briefly, A549 cells (3 × 10 5 per well) in 6-well plates were transfected by ZD55-IL-24 (10 multiplicity of infection (MOI)) for 36 h, then were treated with p38 inhibitor SB203580 (10 μM) and ERK inhibitor U0126 MDA-7/IL-24 inhibits Nrf2-mediated antioxidant response H Tian et al (10 μM) for 6 h, then these cells were briefly washed with ice-cold PBS twice and incubated in 200 μl 1 × binding buffer containing 5 μl Annexin V-FITC for 15 min and then in 300 μl 1 × binding buffer containing 5 μl propidium iodide for 5 min at room temperature in the dark. After incubation, the cells were analyzed by a FACStar flow cytometer (BD Biosciences, San Jose, CA, USA).
Statistical analysis
Values are expressed as mean ± s.d. Statistical analysis of the results was carried out using the Student's t-test or one-way analysis of the variance followed by the Duncan's new multiple range method or Newman-Keuls test. P-values o0.05 were considered as significant.
RESULTS
Effect of ZD55-IL-24 on activation of the MAPK signal pathways
We first detected IL-24 and E1A protein expressions accompanied with transfection of tumor-selective replicating adenovirus ZD55-IL-24 into A549 and HeLa cells. As shown in Figure 1a , a distinct increase in ZD55-IL-24 from 1.2-fold at 24 h to 3.0-fold at 72 h compared with controls was observed in A549 and HeLa cells. Moreover, E1A protein standing for replication ability of ZD55-IL-24 exhibited the obvious enhancement from 24 to 72 h. To determine whether these MAPK signal pathways are involved in ZD55-IL-24-induced cancer cell apoptosis, three MAPK proteins including JNK1/2(p46/p54), ERK1/2(p42/p44) and p38 were detected at the different points after transfection of ZD55-IL-24 in A549 and HeLa cells (Figures 1b-d) . These findings showed that ZD55-IL-24 did not significantly affect expression of these MAPK proteins. However, phospho-JNK1/2(Thr183/Tyr185) and phospho-p38 MAPK (Thr180/ Tyr182) were augmented, whereas phospho-ERK1/2 (Thr202/ Tyr204) was suppressed with extension of ZD55-IL-24 treatment. Our results indicated that ZD55-IL-24 activated JNK and p38 signal pathways but inhibited ERK signal pathway.
Effect of ZD55-IL-24 on the Nrf2 and Keap1 subcellular localization and the association of Nrf2 with Keap1 Given that Nrf2 has a critical role in cellular protection through upregulation of antioxidant genes to resist the oxidative stress, we assessed the effect of ZD55-IL-24 on the subcellular localization of Nrf2 in A549 and HeLa cells, respectively. Our results showed that Nrf2 increased from 1.1-fold at 24 h to 1.62-fold at 72 h compared with the control group in cytosolic fraction, as shown in Figure 2a . However, Nrf2 reduced from 86% at 24 h to 35% at 72 h compared with the control group in the corresponding nuclear fraction. Our data revealed that ZD55-IL-24 led to prevention of Nrf2 nuclear translocation. Several studies have demonstrated that Keap1 possesses the dual functions on sensing a disturbance in the redox homeostasis and switching its substrate Nrf2 on or off. To further determine whether ZD55-IL-24 could affect Nrf2-induced antioxidant response through Keap1, we detected the subcellular localization of Keap1 and the association of Nrf2 and Keap1. As shown in Figure 2b , ZD55-IL-24 led to obvious cytoplasmic accumulation of Keap1, whereas Keap1 was attenuated in the corresponding nuclear fraction of A549 and HeLa cells. In addition, the association of Keap1 with Nrf2 significantly was enhanced in the cytoplasm compared with untreated control group, which means ZD55-IL-24 strengthened the connection of Nrf2 with Keap1. Given that phosphorylation of Nrf2 at Ser40 leads to dissociation of Nrf2 from Keap1 and destabilization of the dimerization of Keap1, we next examined the phosphorylation of Nrf2 at Ser40 in response to ZD55-IL-24. Our data demonstrated that ZD55-IL-24 significantly induced Nrf2 phosphorylation diminishment at Ser40 (Figure 2c ). Taken together, these results clearly suggested that ZD55-IL-24 inhibited Nrf2 phosphorylation at Ser40, which prevented the dissociation of Nrf2 from Keap1 and thus postponed Nrf2 nuclear translocation.
ZD55-IL-24 potentiated the association of Nrf2 and Keap1 through activation of p38 MAPK signal pathway, but restrained Nrf2 nuclear translocation through suppression of ERK signal pathway To further confirm the relationship between ZD55-IL-24 and MAPK signal pathways, the specific IL-24-siRNA was used to knockdown IL-24 expression. As shown in Figure 3a , these data indicated that IL-24-siRNA efficiently inhibited JNK and p38 phosphorylation but restored ERK phosphorylation compared with the scrambled control siRNA, suggesting that ZD55-IL-24 induced the activation of JNK and p38 signal pathways and the inactivation of ERK signal pathway, which is consistent with our previous results. However, whether the alteration in these MAPK signal pathways might be implicated in the regulation of Nrf2 subcellular localization as well as the association of Nrf2 with Keap1 remained unclear. Thus, we analyzed the effect of the different inhibitors of the MAPK signal pathways on ZD55-IL-24-mediated Nrf2 cytoplasm accumulation and Keap1-Nrf2 complex stability. A549 cells were treated with JNK-specific antagonist SB600125, p38 inhibitor SB203580 and ERK-specific inhibitor U0126 after transfection of ZD55-IL-24, respectively. As shown in Figure 3b , no obvious difference in Nrf2 subcellular localization or association of Nrf2 with Keap1 was observed after addition of JNK inhibitor SB600125. However, p38 MAPK pathway inhibitor SB203580 markedly diminished the association of Nrf2 and Keap1 and thus facilitated Nrf2 nuclear translocation, but not affected Nrf2 phosphorylation at Ser40 (Figure 3c ). In contrast, ERK inhibitor U0126 further attenuated the phosphorylation of Nrf2 at Ser40 compared with transfection of ZD55-IL-24 only, which potentiated Nrf2 cytoplasmic accumulation in Figure 3d . In addition, immunocytofluorescence staining was used to further confirm that ZD55-IL-24 regulated the subcellular localization of Nrf2 via these MAPK signal pathways. As shown in Figure 4 , our data showed that ZD55-IL-24 obviously induced Nrf2 cytoplasm accumulation and restrained Nrf2 nuclear translocation compared with the control group. In addition, p38 signal pathway inhibitor SB203580 diminished the association of Nrf2 with Keap1, which triggered Nrf2 translocation from cytoplasm to nucleus. However, ERK pathway inhibitor U0126 exerted the opposite effect to inhibit Nrf2 nuclear translocation. Similarly, JNK pathway inhibitor SB600125 had no significant effect on the stability of Keap1-Nrf2 complex and the subcellular localization of Nrf2 compared with DMSO control group. Conclusively, ZD55-IL-24 upregulated p38 signal pathway to potentiate the association of Nrf2 with Keap1, but downregulated ERK signal pathway to diminish Nrf2 phosphorylation at Ser40, which subsequently inhibited Nrf2 nuclear translocation.
ZD55-IL-24 regulated Nrf2-dependent ARE gene transcription and cancer cell apoptosis through activation of p38 MAPK signal pathway and inhibition of ERK signal pathway To determine whether ZD55-IL-24 could affect Nrf2-ARE gene transcription via three MAPK signal pathways, we analyzed AREmediated reporter gene expression by transient transfection assay. After transfection of A549 cells with ZD55-IL-24 for the different time, the relevant luciferase activity was examined respectively. As shown in Figure 5a , NQO1-ARE transcriptional activity was significantly diminished from 86% at 24 h to 31% at 72 h in response to ZD55-IL-24. To further determine the roles of these MAPK signal pathways in the downregulation of ARE gene transcription induced by ZD55-IL-24, we treated A549 cells with or without the JNK, p38 and ERK pathway inhibitors after transfection of ZD55-IL-24, respectively. As shown in Figure 5b , p38 signal pathway inhibitor SB203580 markedly restored the ZD55-IL-24-mediated ARE-Luc activity, whereas ERK signal pathway inhibitor U0126 exacerbated the ARE-Luc activity. Consistent with the western blotting data, JNK pathway inhibitor SB600125 still had no significant effect on ARE-Luc activity. Considering Nrf2 as cellular defense executor, we wanted to further assess whether Figure 4 . ZD55-IL-24 affects the subcellular localization of nuclear factor erythroid 2-related factor 2 (Nrf2) through p38 and extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) signal pathways. Subcellular localization of Nrf2 with or without JNK1/2 inhibitor SB600125 (50 μM), p38 pathway inhibitor SB203580 (10 μM) and ERK pathway inhibitor U0126 (10 μM) after transfection of ZD55-IL-24 (10 multiplicity of infection (MOI)) was examined by fluorescence microscopy with use of anti-Nrf2 antibody (the first row), DAPI staining nuclear (the second row), and then merged together (the third row) (original magnification, × 400). IL-24, interleukin-24; JNK, c-Jun-NH2-kinase. ARE transcriptional response, but simultaneously suppressed ERK signal pathway to down-egulate antioxidant gene transcription, cooperatively leading to carcinoma cell apoptosis.
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DISCUSSION
The most intriguing property of MDA-7/IL-24 is preferential induction of apoptosis in cancer cells of diverse organ without harming normal cells. 2, 3, 5 The previous report has shown that Ad-IL-24 infection of prostate carcinoma cells results in biochemical changes including mitochondrial dysfunction and ROS induction before the visualization of the apoptotic events. Importantly, Ad-IL-24-induced apoptosis and mitochondrial dysfunction are inhibited by simultaneous treatment with ROS inhibitors, N-acetyl-L-serine and Tiron, but potentiated by treatment with ROS inducers, indicating a definite relationship between oxidative stress and Ad-IL-24-induced cancer cell apoptosis. 34 Facing to this oxidative stress, somatic cells not only cancer cells always trigger their own defense system comprising several phase II detoxification enzymes to neutralize reactive molecules, eliminate damaged macromolecules, reduce inflammation and restore cellular redox homeostasis. However, whether MDA-7/IL-24 could suppress transcription of phase II detoxification enzymes to attenuate cellular protective machinery remains unclear. The present study depicted that ZD55-IL-24 induced p38 and ERK signal pathways responsible for the regulation of Nrf2-mediated ARE gene transcription, which provided the direct evidence that ZD55-IL-24 not only induced ROS-related cytotoxicity but also attenuated the antioxidative response, displaying synergistic effect of cancer-specific killing.
Nrf2 has been identified as a key transcriptional factor of the cell survival response genes through ARE. 20 Recent emerging data reveal the 'dark' side of Nrf2. Nrf2 and its downstream genes are overexpressed in many human cancer tissues, giving cancer cells an advantage for survival and growth. [35] [36] [37] Furthermore, Nrf2 upregulation in resistant cancer cell apoptosis is thought to be responsible for acquired chemoresistance. To be the inhibitor of Nrf2, Keap1 functions as a substrate adaptor protein for a Cul3-Rbx1-dependent E3 ubiquitin ligase complex to ubiquitinate and degrade Nrf2, thus maintaining steady-state levels of Nrf2. However, under oxidative stress, Nrf2 is always dissociated from Keap1, and subsequently translocates into the nucleus, binding to ARE, which activates a battery of cytoprotective genes. In the present study, we found that ZD55-IL-24 prevented the dissociation of Nrf2 from Keap1, inhibited Nrf2 phosphorylation at Ser40 and attenuated Nrf2 translocation from cytoplasm to nucleus as well as downstream ARE gene transcription.
To explore the molecular mechanism underlying this effect, we further investigated the correlation between Nrf2-mediated antioxidative response and the activation of MAPK signal pathways induced by MDA-7/IL-24. Sarkar et al. 32 has reported that p38 MAPK and its downstream GADD family of genes have a crucial role in the cancer-selective apoptosis inducing effect of MDA-7/ IL-24 in melanoma cells. In addition, MDA-7/IL-24 suppresses ERK1/2 pathway mediated by activation of protein kinase R-like endoplasmic reticulum kinase to promote growth arrest and cell death. 38 Consistent with these previous studies, our current findings also demonstrated that ZD55-IL-24 significantly inhibited p-ERK but increased p-JNK, p-p38 without effect on the expression level of three MAPK proteins, suggesting that ZD55-IL-24 regulated MAPK signal pathways differently to induce cancer cell apoptosis. To confirm the relationship between ZD55-L-24 and three MAPK signal pathways, IL-24-siRNA was used to knockdown IL-24 to block phosphorylation of JNK and p38 MAPK signal pathways but restore that of ERK signal pathway, indicating that ZD55-IL-24 activated JNK and p38 MAPK signal pathways but Figure 6 . Schematic model of melanoma differentiation-associated gene-7 (MDA-7)/IL-24 inhibit nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant response element (ARE) gene transcription through activation of p38 and inhibition of extracellular signalregulated kinase (ERK) signal pathway leading to cancer cell apoptosis. (I) MDA-7/IL-24 activates p38 pathway, which phosphates Nrf2 at some amino acid except for Ser40 to stabilize the interaction between Nrf2 and Kelch-like ECH-associated protein-1 (Keap1) proteins, and thereby suppresses Nrf2 nuclear translocation. (II) MDA-7/IL-24 inhibits ERK pathway that facilitates Nrf2 phosphorylation at Ser40 to induce Nrf2 nuclear translocation. (III) Nrf2 dissociated from Keap1 complex translocates into nucleus and then activates ARE-mediated phase II antioxidant gene expression, leading to the resistance of cancer cell apoptosis. IL-24, interleukin-24.
inhibited ERK signal pathway to exert cancer cell-specific apoptosis.
Since Nrf2-ARE antioxidant gene transcription is partially attributed to activation of some MAPK signal pathways, [39] [40] [41] we used the different antagonists to observe the corresponding effects of these MAPK proteins on the association of Nrf2 with Keap1, Nrf2 nuclear translocation and downstream ARE-mediated antioxidant gene transcription in response to ZD55-IL-24. Our results showed that the addition of p38-specific antagonist SB203580 obviously induced the dissociation of Nrf2 from Keap1, which disrupted the Keap1-Nrf2 complex stabilization. Nrf2 transferred from the cytoplasm to the nucleus where Nrf2 bound to ARE-mediated phase II genes through the heterodimeric combination with other basic leucine zipper proteins to trigger their transcription. One possible explanation could be that p38 MAPK can phosphate Nrf2 at the other amino acid except for Ser40, which inhibits the dissociation of Nrf2 from Keap1. 42 However, our data demonstrated ERK signal pathway inhibitor U0126 restrained Nrf2 phosphorylation at Ser40. Considering that ERK activation is required for Nrf2 nuclear localization, 43 ERKdependent phosphorylation of Nrf2 at Ser40 maybe provides a reasonable explanation for Nrf2 nuclear translocation. Interestingly, according to our study, treatment of SB600125, a chemical inhibitor of JNK MAPK signal pathway, had no effect on Nrf2 phosphorylation or Keap1-Nrf2 complex stability. Collectively, ZD55-IL-24 restricted Nrf2 phosphorylation at Ser40 to inhibit Nrf2 nuclear translocation via ERK signal pathway, but restrained the dissociation of Nrf2 from Keap1 through activation of p38 MAPK signal pathway, which cooperatively prevented Nrf2 from initiating ARE-mediated Phase II gene transcription.
In summary, ZD55-IL-24 regulates Nrf2-mediated cellular defense system via two MAPK signal pathways to trigger cancerspecific killing. As shown in Figure 6 , on one side, ZD55-IL-24 induces p38 MAPK signal pathway to inhibit the dissociation of Nrf2 from Keap1. On the other side, ZD55-IL-24 suppresses ERK signal pathway to restrain Nrf2 phosphorylation at Ser40, which prevents Nrf2 from nuclear translocation. Both collectively attenuate the ARE-dependent phase II enzymes transcription. Given that Nrf2 has a crucial role not only in oxidative stressmediated cellular defense system but also in cancer chemoresistance and its malignant transformation, it is important to clarify that MDA-7/IL-24 represses Nrf2 to postpone phase II genes transcription via ERK and p38 MAPK signal pathways. Further investigations to identify the relationship between Keap1-Nrf2 complex mediated protective response and MDA-7/IL-24 induced cancer selective apoptosis may provide robust evidence on this cytokine potential therapeutic application.
